Biogen (BIIB) Tmuɣli n wazal
Ṛṛbem n lḥedd$227.93Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel+0.69%
Asnulfu n AI: BIIB
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
Biogen Inc. develops, manufactures, and commercializes therapies with a focus on neurology, oncology, and immunology. The company’s products are designed to treat conditions such as multiple sclerosis, non-Hodgkin lymphoma, rheumatoid arthritis, Crohn’s disease, and psoriasis.
